MEP32208A - Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients - Google Patents

Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients

Info

Publication number
MEP32208A
MEP32208A MEP-322/08A MEP32208A MEP32208A ME P32208 A MEP32208 A ME P32208A ME P32208 A MEP32208 A ME P32208A ME P32208 A MEP32208 A ME P32208A
Authority
ME
Montenegro
Prior art keywords
active ingredients
combination
agonist
lasting
beta2
Prior art date
Application number
MEP-322/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Roberta Razzetti
Fiorella Pastore
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP32208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MEP32208A publication Critical patent/MEP32208A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MEP-322/08A 2003-02-27 2004-02-27 Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients MEP32208A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03004184A EP1452179A1 (fr) 2003-02-27 2003-02-27 Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
YUP-2005/0615A RS20050615A (sr) 2003-02-27 2004-02-27 Lek koji sadrži visoko potentni dugotrajni beta2-agonist u kombinaciji sa drugim aktivnim sastojcima
PCT/EP2004/001960 WO2004075896A1 (fr) 2003-02-27 2004-02-27 Medicament comportant un agoniste beta 2 de longue duree et tres puissant en combinaison avec d'autres ingredients actifs

Publications (1)

Publication Number Publication Date
MEP32208A true MEP32208A (en) 2010-10-10

Family

ID=32748803

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-322/08A MEP32208A (en) 2003-02-27 2004-02-27 Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients

Country Status (31)

Country Link
US (1) US20070020190A1 (fr)
EP (3) EP1452179A1 (fr)
JP (1) JP2006519204A (fr)
KR (1) KR20050104367A (fr)
CN (2) CN100370986C (fr)
AR (1) AR043419A1 (fr)
AT (1) ATE401887T1 (fr)
AU (1) AU2004216472B2 (fr)
BR (1) BRPI0408047A (fr)
CA (1) CA2517321A1 (fr)
CY (1) CY1108360T1 (fr)
DE (1) DE602004015260D1 (fr)
DK (1) DK1603565T3 (fr)
EA (1) EA008828B1 (fr)
ES (1) ES2309503T3 (fr)
HR (1) HRP20050726A2 (fr)
MA (1) MA27630A1 (fr)
ME (1) MEP32208A (fr)
MX (1) MXPA05009007A (fr)
NO (1) NO20053959L (fr)
NZ (1) NZ541997A (fr)
PE (1) PE20050290A1 (fr)
PL (1) PL377814A1 (fr)
PT (1) PT1603565E (fr)
RS (1) RS20050615A (fr)
SA (1) SA04250122B1 (fr)
SI (1) SI1603565T1 (fr)
TN (1) TNSN05186A1 (fr)
UA (1) UA82217C2 (fr)
WO (1) WO2004075896A1 (fr)
ZA (1) ZA200506820B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP2007500676A (ja) * 2003-07-31 2007-01-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
EP1654001A2 (fr) * 2003-08-05 2006-05-10 Boehringer Ingelheim International GmbH Medicament pour inhalation comprenant des steroides et un betamimetique
PT1670482E (pt) * 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
EP1863476B1 (fr) * 2005-03-16 2016-02-03 MEDA Pharma GmbH & Co. KG Combinaison d'anticholinergiques et d'antagonistes de recepteur de leukotriene permettant de traiter les maladies respiratoires
EP2484382A1 (fr) * 2005-03-30 2012-08-08 Schering Corporation Médicament à base d'un inhibiteur de la phosphodiestérase IV sous une forme adaptée à l'inhalation
CA2617286A1 (fr) * 2005-08-01 2007-02-08 Chiesi Farmaceutici S.P.A. Formulations pharmaceutiques comprenant un agoniste beta2 a longue duree d'action administrees par nebulisation
ATE529399T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
NZ591969A (en) * 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
JP2010526763A (ja) * 2006-05-24 2010-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患を治療するための新規な長時間作用型の薬剤組成物
EP1953143A1 (fr) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Processus de préparation de monohydrochloride de 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1H)-quinolinone
EP2124915A2 (fr) * 2007-02-19 2009-12-02 Cipla Limited Combinaisons pharmaceutiques
EP2534957B1 (fr) 2007-12-14 2015-05-27 AeroDesigns, Inc Administration de produits sous forme d'aérosols
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
WO2010097188A1 (fr) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Particules pour inhalation comprenant un sel de carmotérol et un corticostéroïde
BRPI1008165B1 (pt) * 2009-05-25 2020-02-27 Chiesi Farmaceutici S.P.A. Uma combinação terapêutica compreendendo um surfactante pulmonar e um esteróide
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
PL3111927T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
WO2011136753A1 (fr) * 2010-04-26 2011-11-03 Mahmut Bilgic Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires
CN102247597B (zh) * 2010-05-19 2015-01-07 天津金耀集团有限公司 一种糖皮质激素与支气管扩张剂的吸入剂
CN103096897A (zh) * 2010-07-16 2013-05-08 希普拉有限公司 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
WO2012010854A1 (fr) 2010-07-23 2012-01-26 Cipla Limited Composition pharmaceutique
CN102416179B (zh) * 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
TWI399202B (zh) * 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
EP2968312B1 (fr) * 2013-03-15 2018-01-31 Verona Pharma PLC Association de médicaments
CA2961410C (fr) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Composition cannabinoide et methode de traitement de la douleur
US11026918B2 (en) 2014-11-24 2021-06-08 The Board Of Trustees Of The University Of Illinois Method of preventing or treating a pulmonary disease or condition
US10751300B2 (en) 2015-01-25 2020-08-25 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2017027651A1 (fr) * 2015-08-12 2017-02-16 India Globalization Capital, Inc. Méthode et composition pour traiter la cachexie et les troubles de l'alimentation
EP3471746A4 (fr) 2016-06-15 2020-02-26 India Globalization Capital, Inc. Méthode et composition pour traiter des troubles epileptiques
CN115337311B (zh) * 2022-09-26 2023-05-09 南京恒道医药科技股份有限公司 一种治疗呼吸系统疾病的组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO1998041193A1 (fr) * 1997-03-20 1998-09-24 Schering Corporation Preparation d'agglomerats de poudre
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US20020081266A1 (en) * 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AU2000250701B2 (en) * 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
ES2342463T3 (es) * 2002-03-01 2010-07-07 Chiesi Farmaceutici S.P.A. Formulacion superfina de formoterol.
EP1340492A1 (fr) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formulations d'aérosol pour l'administration par voie pulmonaire de medicaments avec effet systémique
EP1595531A1 (fr) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Formulation d'une solution pharmaceutique stable pour aérosols doseurs sous pression

Also Published As

Publication number Publication date
PE20050290A1 (es) 2005-05-26
EA200501108A1 (ru) 2006-04-28
DK1603565T3 (da) 2008-11-10
EP1603565B1 (fr) 2008-07-23
CN101244063A (zh) 2008-08-20
AU2004216472B2 (en) 2009-08-06
HRP20050726A2 (en) 2006-02-28
SA04250122B1 (ar) 2009-03-11
NZ541997A (en) 2008-12-24
HK1087009A1 (en) 2006-10-06
US20070020190A1 (en) 2007-01-25
CY1108360T1 (el) 2014-02-12
NO20053959D0 (no) 2005-08-25
ZA200506820B (en) 2006-11-29
AU2004216472A1 (en) 2004-09-10
SI1603565T1 (sl) 2008-10-31
JP2006519204A (ja) 2006-08-24
ATE401887T1 (de) 2008-08-15
DE602004015260D1 (de) 2008-09-04
ES2309503T3 (es) 2008-12-16
NO20053959L (no) 2005-11-28
MA27630A1 (fr) 2005-11-01
EP1452179A1 (fr) 2004-09-01
WO2004075896A1 (fr) 2004-09-10
UA82217C2 (uk) 2008-03-25
PL377814A1 (pl) 2006-02-20
KR20050104367A (ko) 2005-11-02
EP1603565A1 (fr) 2005-12-14
AR043419A1 (es) 2005-07-27
BRPI0408047A (pt) 2006-02-14
PT1603565E (pt) 2008-10-06
CA2517321A1 (fr) 2004-09-10
CN1753678A (zh) 2006-03-29
MXPA05009007A (es) 2005-10-18
RS20050615A (sr) 2007-09-21
EP1834643A2 (fr) 2007-09-19
EA008828B1 (ru) 2007-08-31
EP1834643A3 (fr) 2007-10-24
CN100370986C (zh) 2008-02-27
TNSN05186A1 (en) 2007-06-11

Similar Documents

Publication Publication Date Title
MEP32208A (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
FI20002215A0 (fi) Yhdistelmäpartikkelit
BRPI0110947B8 (pt) processo para a preparação de uma composição farmacêutica e composição farmacêutica assim obtida
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
MXPA02011311A (es) Composicion novedosa.
IL161290A0 (en) Stable composition comprising particles in a frozen aqueous matrix
HRP20080439T3 (hr) Nova kombinacija antikolinergika i beta mimetika za liječenje respiratornih bolesti
DE60120936D1 (de) Behandlung von atemerkrankungen
CL2003002746A1 (es) Compuesto derivado de piridazin-3(2h)-ona sustituida en las posiciones 4,5,6; procedimiento de preparacion de dicho compuesto; compuesto intermediario; composicion farmaceutica; y el uso del compuesto para el tratamiento del asma, enfermedad pulmonar
UA84048C2 (ru) Производные сульфонамида для лечения заболеваний, способ их получения (варианты), фармацевтическая композиция на их основе
BR0210473A (pt) Composição compreendendo um inibidor da pde-4 e antagonista do receptor-h1 e seus usos na produção de um medicamento para o tratamento de doenças respiratórias
YU58398A (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use the terapy of hiv
NO20080950L (no) Topiske formuleringer inneholdende O-desmetylvenlafaksin (ODV) eller salter derav
WO2005025498A3 (fr) Acetanilides et benzamides substitues utilises dans le traitement de l'asthme et des inflammations pulmonaires
UY29445A1 (es) Composiciones para la transmisión transmucosa oral de la metformina
WO2005011602A3 (fr) Combinaison de dehydroepiandrosterone ou de sulfate de dehydroepiandrosterone et d'un inhibiteur de pde-4 pour le traitement de l'asthme ou d'une maladie obstructive respiratoire
UY28096A1 (es) Nueva formulación pulveurlenta que contiene tiotropio destinada a la inhalación
WO2005011615A3 (fr) Combinaison de deshydroepiandrosterone ou de sulfate de deshydroepiandrosterone avec un bronchodilatateur anticholinergique pour le traitement de l'asthme ou de la bronchopneumopathie obstructive chronique
WO2005011603A3 (fr) COMBINAISON CONSTITUEE DE DESHYDROEPIANDROSTERONE OU DE DESHYDROEPIANDROSTERONE-SULFATE ET D'UN BRONCHODILATATEUR ß-AGONISTE DESTINEE AU TRAITEMENT DE L'ASTHME OU DE LA BRONCHOPNEUMOPATHIE CHRONIQUE OBSTRUCTIVE
WO2007065625A3 (fr) Compositions pharmaceutiques a base d'agents hypnotiques de courte duree d’action, disponibles sous formes a liberation modifiee, et procedes de preparation desdites formulations
ATE369121T1 (de) Bimodale trockenpulverzusammensetzung zur inhalation
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
WO2005011613A8 (fr) Combinaison de deshydroepiandrosterone ou de sulfate de deshydroepiandrosterone avec un inhibiteur de la lipoxygenase pour le traitement de l'asthme ou de la bronchopneumopathie obstructive chronique
HRP20050580B1 (hr) Sinergistiäśki uäśinak kombinacije roflumilasta i (r,r)-formoterola
FR2809725B1 (fr) Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant